KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CRISPR Therapeutics AG (CRSP) EPS (Weighted Average and Diluted): 2017-2024

Historic EPS (Weighted Average and Diluted) for CRISPR Therapeutics AG (CRSP) over the last 8 years, with Dec 2024 value amounting to -$4.34.

  • CRISPR Therapeutics AG's EPS (Weighted Average and Diluted) fell 15.84% to -$1.17 in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.57, marking a year-over-year decrease of 98.93%. This contributed to the annual value of -$4.34 for FY2024, which is 123.71% down from last year.
  • CRISPR Therapeutics AG's EPS (Weighted Average and Diluted) amounted to -$4.34 in FY2024, which was down 123.71% from -$1.94 recorded in FY2023.
  • CRISPR Therapeutics AG's EPS (Weighted Average and Diluted)'s 5-year high stood at $4.70 during FY2021, with a 5-year trough of -$8.36 in FY2022.
  • For the 3-year period, CRISPR Therapeutics AG's EPS (Weighted Average and Diluted) averaged around -$4.88, with its median value being -$4.34 (2024).
  • In the last 5 years, CRISPR Therapeutics AG's EPS (Weighted Average and Diluted) plummeted by 552.14% in 2020 and then skyrocketed by 188.85% in 2021.
  • CRISPR Therapeutics AG's EPS (Weighted Average and Diluted) (Yearly) stood at -$5.29 in 2020, then soared by 188.85% to $4.70 in 2021, then crashed by 277.87% to -$8.36 in 2022, then surged by 76.79% to -$1.94 in 2023, then crashed by 123.71% to -$4.34 in 2024.